| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Other names | VBI-2902a |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
N VBI-2902 is aCOVID-19 vaccine candidate developed byVariation Biotechnologies from theUnited States.[2]
In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".[3] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein".[3] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.[3][4][5] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.[6]
{{cite journal}}:Cite journal requires|journal= (help)
.png) | This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |
 | This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it. |
